Haemoglobin-based oxygen carriers and myocardial infarction
Source abstract
Abstract
The incidence of investigator diagnosed myocardial infarction (MI) is greater in patients treated with haemoglobin-based oxygen carriers (HBOCs) than controls. Clinical trials and literature pertaining to possible HBOC toxicity mechanisms have been analyzed in order to identify possible reasons for this imbalance. MI diagnosis is hampered by potential interference of troponin assays by haemoglobin, haemolysis and bilirubin. Nevertheless, insofar as the reported incidence correlates with actual occurrence, there is a positive relationship between MI and HBOC dose and size. Preclinical and clinical data suggest that direct cardiac toxicity and coronary vasoconstriction are unlikely. More probable are detrimental intravascular interactions between HBOCs and components of the coagulation cascade, particularly dysfunctional endothelium. Elucidation of mechanisms is impeded by a lack of clinical data. Measurement of relevant biomarkers would be extremely useful in this regard and in improving patient selection criteria. Conduct of clinical trials in carefully selected patient populations after the development of improved protocols for MI diagnosis, along with concomitant biomarker data collection, is recommended.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Hemoglobin structure and function · Heme Oxygenase-1 and Carbon Monoxide · Nitric Oxide and Endothelin Effects
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Chart Biotech Consulting, LLC
References (97)
Show source-provided references
1. 10.1001/jama.299.19.jrv8000710.1001/jama.299.19.jrv80007 ↗
2. 10.1111/j.1365-3148.2007.00811.x10.1111/j.1365-3148.2007.00811.x ↗
3. 10.1097/ALN.0b013e318215e19810.1097/ALN.0b013e318215e198 ↗
4. 10.1097/TA.0b013e318173a93f10.1097/TA.0b013e318173a93f ↗
5. 10.1213/ANE.000000000000030510.1213/ANE.0000000000000305 ↗
6. 10.1016/j.jamcollsurg.2008.09.02310.1016/j.jamcollsurg.2008.09.023 ↗
7. 10.1111/j.1537-2995.2009.02356.x10.1111/j.1537-2995.2009.02356.x ↗
8. 10.1016/S0301-4622(97)00079-310.1016/S0301-4622(97)00079-3 ↗
9. Nelson DJ. Hemassist™: development and clinical profile. In: Rudolph AS, Rabinovici R, Feuerstein GZ, editors. Red blood cell substitutes basic principles and clinical applications. New York(NY): Marcel Dekker; 1998. p. 353–400.
10. 10.1046/j.1537-2995.2003.00341.x10.1046/j.1537-2995.2003.00341.x ↗
11. 10.4244/EIJV4I1A2610.4244/EIJV4I1A26 ↗
12. 10.1016/0955-3886(95)93436-A10.1016/0955-3886(95)93436-A ↗
13. 10.1016/S1072-7515(98)00095-710.1016/S1072-7515(98)00095-7 ↗
14. 10.1002/bip.1969.36008051410.1002/bip.1969.360080514 ↗
15. 10.1016/S0167-4838(99)00211-310.1016/S0167-4838(99)00211-3 ↗
16. 10.1021/bc900130f10.1021/bc900130f ↗
17. Biopure. Scientific commentary on the Natanson et al. meta-analysis. [Online] 2008 [cited 2008 October 16]; Available from: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1807-59322009000800016.
18. 10.3109/21691401.2015.104750110.3109/21691401.2015.1047501 ↗
19. 10.1093/eurheartj/ehs18410.1093/eurheartj/ehs184 ↗
20. 10.1503/cmaj/05129110.1503/cmaj/051291 ↗
21. 10.1002/jcla.510.1002/jcla.5 ↗
22. 10.1515/CCLM.1999.01110.1515/CCLM.1999.011 ↗
23. 10.1258/00045630677514168710.1258/000456306775141687 ↗
24. 10.1093/clinchem/43.9.173210.1093/clinchem/43.9.1732 ↗
25. 10.1016/j.clinbiochem.2008.10.02310.1016/j.clinbiochem.2008.10.023 ↗
26. Björkholm M, Fagrell B, Przybelski R, et al. A phase I single blind clinical trial of a new oxygen transport agent (MP4), human hemoglobin modified with maleimide-activated polyethylene glycol. Haematologica. 2005;90:505–515.
27. 10.1093/clinchem/44.6.119810.1093/clinchem/44.6.1198 ↗
28. 10.1097/TA.0b013e3181820d5c10.1097/TA.0b013e3181820d5c ↗
29. 10.1007/978-3-642-40717-8_3210.1007/978-3-642-40717-8_32 ↗
30. Vogel WM, Dennis RC, Cassidy G, et al. Coronary constrictor effect of stroma-free hemoglobin solutions. Am J Physiol. 1986;251:H413–H420.
31. 10.3109/1073119900911730610.3109/10731199009117306 ↗
32. 10.1016/0024-3205(87)90560-110.1016/0024-3205(87)90560-1 ↗
33. 10.3109/1073119940911788810.3109/10731199409117888 ↗
34. 10.1081/BIO-12000319410.1081/BIO-120003194 ↗
35. 10.1152/ajpheart.00905.200410.1152/ajpheart.00905.2004 ↗
36. 10.1097/00003246-199604000-0000310.1097/00003246-199604000-00003 ↗
37. 10.1093/cvr/28.8.118810.1093/cvr/28.8.1188 ↗
38. 10.1097/01.TA.0000101391.58216.DD10.1097/01.TA.0000101391.58216.DD ↗
39. 10.1097/TA.0b013e318183803010.1097/TA.0b013e3181838030 ↗
40. 10.4244/EIJV3I5A10810.4244/EIJV3I5A108 ↗
41. 10.4244/EIJV4I1A1710.4244/EIJV4I1A17 ↗
42. 10.1016/j.freeradbiomed.2003.11.03010.1016/j.freeradbiomed.2003.11.030 ↗
43. 10.1097/ALN.0b013e3181cd783810.1097/ALN.0b013e3181cd7838 ↗
44. 10.2174/15701631280265073310.2174/157016312802650733 ↗
45. 10.1046/j.1365-2044.2002.02782_1.x10.1046/j.1365-2044.2002.02782_1.x ↗
46. 10.1007/s00134-002-1558-110.1007/s00134-002-1558-1 ↗
47. 10.1046/j.1365-2141.2003.04068.x10.1046/j.1365-2141.2003.04068.x ↗
48. 10.1182/blood.V96.10.363010.1182/blood.V96.10.3630 ↗
49. 10.1053/j.jvca.2007.02.01610.1053/j.jvca.2007.02.016 ↗
50. 10.3109/1073119920911968610.3109/10731199209119686 ↗
51. 10.1161/01.CIR.93.2.32710.1161/01.CIR.93.2.327 ↗
52. 10.1213/01.ANE.0000099366.73625.DD10.1213/01.ANE.0000099366.73625.DD ↗
53. 10.1097/01.shk.0000170354.18437.2f10.1097/01.shk.0000170354.18437.2f ↗
54. 10.1097/00003246-199612000-0001110.1097/00003246-199612000-00011 ↗
55. 10.1097/00003246-200007000-0001710.1097/00003246-200007000-00017 ↗
56. 10.1017/S1049023X0002772210.1017/S1049023X00027722 ↗
57. 10.1213/01.ANE.0000068888.02977.DA10.1213/01.ANE.0000068888.02977.DA ↗
58. Hughes GS, Francom SF, Antal EJ, et al. Hematologic effects of a novel hemoglobin-based oxygen carrier in normal male and female subjects. J Lab Clin Med. 1995;126:444–451.
59. 10.1097/MJT.0b013e3181a2b08d10.1097/MJT.0b013e3181a2b08d ↗
60. Burhop KE, Goldberg CM, Balma D, et al. Effects of diaspirin cross-linked hemoglobin (DCLHb) on hematologic variables [abstract]. Blood. 1992;80:221a.
61. 10.1093/bja/80.2.18910.1093/bja/80.2.189 ↗
62. 10.1097/00000539-200204000-0000610.1097/00000539-200204000-00006 ↗
63. 10.1097/00002480-199809000-0000710.1097/00002480-199809000-00007 ↗
64. 10.1152/ajpheart.1995.269.2.H64810.1152/ajpheart.1995.269.2.H648 ↗
65. 10.1152/ajpheart.1998.275.3.H104610.1152/ajpheart.1998.275.3.H1046 ↗
66. 10.1007/978-3-642-40717-8_3510.1007/978-3-642-40717-8_35 ↗
67. 10.1152/ajpheart.00164.200410.1152/ajpheart.00164.2004 ↗
68. 10.1182/blood-2013-04-49588710.1182/blood-2013-04-495887 ↗
69. 10.1089/ars.2007.178710.1089/ars.2007.1787 ↗
70. 10.1161/ATVBAHA.110.20643310.1161/ATVBAHA.110.206433 ↗
71. 10.1016/j.jamcollsurg.2005.05.01110.1016/j.jamcollsurg.2005.05.011 ↗
72. 10.1073/pnas.92.15.679810.1073/pnas.92.15.6798 ↗
73. 10.1172/JCI416510.1172/JCI4165 ↗
74. 10.1055/s-0031-130095010.1055/s-0031-1300950 ↗
75. 10.1182/blood-2004-06-209610.1182/blood-2004-06-2096 ↗
76. 10.2174/15701611280352073810.2174/157016112803520738 ↗
77. 10.1074/jbc.M31356020010.1074/jbc.M313560200 ↗
78. 10.1182/blood.V85.11.3164.bloodjournal8511316410.1182/blood.V85.11.3164.bloodjournal85113164 ↗
79. 10.3109/1073119900911730710.3109/10731199009117307 ↗
80. Feola M, Simoni J, Canizaro PC, et al. Toxicity of polymerized hemoglobin solutions. Surg Gynecol Obstet. 1988;166:211–222.
81. 10.1081/BIO-20002742910.1081/BIO-200027429 ↗
82. 10.1097/SHK.0b013e31821366f610.1097/SHK.0b013e31821366f6 ↗
83. 10.1016/j.trsl.2006.09.00710.1016/j.trsl.2006.09.007 ↗
84. 10.1152/ajpheart.00076.200610.1152/ajpheart.00076.2006 ↗
85. 10.1152/ajpheart.00667.200910.1152/ajpheart.00667.2009 ↗
86. 10.1016/S0952-8180(03)00026-610.1016/S0952-8180(03)00026-6 ↗
87. 10.1097/00000542-200003000-0003910.1097/00000542-200003000-00039 ↗
88. 10.1056/NEJM20000601342220410.1056/NEJM200006013422204 ↗
89. 10.5694/j.1326-5377.2011.tb03064.x10.5694/j.1326-5377.2011.tb03064.x ↗
90. 10.1007/978-3-642-40717-8_2910.1007/978-3-642-40717-8_29 ↗
91. 10.1007/978-3-642-40717-8_3010.1007/978-3-642-40717-8_30 ↗
92. 10.1172/JCI20052440810.1172/JCI200524408 ↗
93. 10.1161/CIRCULATIONAHA.105.60551910.1161/CIRCULATIONAHA.105.605519 ↗
94. 10.1006/bbrc.1997.792810.1006/bbrc.1997.7928 ↗
95. 10.2147/CIA.S15851310.2147/CIA.S158513 ↗
96. 10.1007/978-3-642-40717-8_3310.1007/978-3-642-40717-8_33 ↗
97. 10.1111/trf.1233910.1111/trf.12339 ↗